Last reviewed · How we verify
Berberine;Atorvastatin or Rosuvastatin
This combination uses berberine to enhance lipid metabolism and reduce cholesterol synthesis, paired with a statin (atorvastatin or rosuvastatin) to inhibit HMG-CoA reductase for additive LDL-lowering effects.
This combination uses berberine to enhance lipid metabolism and reduce cholesterol synthesis, paired with a statin (atorvastatin or rosuvastatin) to inhibit HMG-CoA reductase for additive LDL-lowering effects. Used for Hyperlipidemia and dyslipidemia management, Cardiovascular risk reduction in patients with elevated cholesterol.
At a glance
| Generic name | Berberine;Atorvastatin or Rosuvastatin |
|---|---|
| Also known as | Berberine;, Liptor, Crestor |
| Sponsor | Wenzhou Medical University |
| Drug class | Combination lipid-lowering agent (natural alkaloid + statin) |
| Target | AMPK (berberine); HMG-CoA reductase (statin component) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Berberine activates AMP-activated protein kinase (AMPK) and upregulates LDL receptor expression, improving cholesterol clearance. When combined with statins, which directly inhibit the rate-limiting enzyme in cholesterol synthesis, the dual mechanism provides synergistic reduction in serum LDL cholesterol and triglycerides. This combination targets hyperlipidemia through complementary pathways.
Approved indications
- Hyperlipidemia and dyslipidemia management
- Cardiovascular risk reduction in patients with elevated cholesterol
Common side effects
- Muscle pain or myalgia
- Elevated liver enzymes
- Gastrointestinal upset
- Headache
Key clinical trials
- Effect of Berberine for Endothelial Function and Intestinal Microflora in Patients With Coronary Artery Disease (PHASE1, PHASE2)
- The Therapeutic Effects of Statins and Berberine on the Hyperlipemia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |